Indegene Ltd Q1 FY2026 Concall Summary

Key Takeaways

• Revenue hit by onetime items, not demand erosion: USD revenue growth was 2.2% QoQ before a onetime customer credit and a Brand Activation project deferral; the underlying enterprise business (86.6% of revenue) remains non-discretionary and stable.
• Tectonic launch opens a new revenue pool: Indegene's move up the marketing value chain generated over \$1 million in Q1 from two top-20 customers, targeting the 5–15% of pharma marketing budgets traditionally held by agencies.
• Margins held steady at ~20% EBITDA: Productivity gains from automation and Gen AI offset wage hikes and POC investments; management commits to sustaining this level near-term while prioritizing growth reinvestment over margin expansion.
• M&A expectations are finally resetting: Seller valuation expectations are coming down from 2021–22 euphoria, making management "more bullish" on closing deals; a healthy pipeline spans both the U.S. and Europe.
• What to watch next quarter: Whether the two large deals (one ECS going live in Q2, one Brand Activation in H2) convert to revenue, the pace of Tectonic's scaling across three more advanced-stage customers, and the margin impact of July 1 wage hikes.

Revenue Headwinds: Onetime, Not Structural

• Onetime credit masked underlying growth: A credit given to a customer to settle unresolved project expenses from a mid-last-fiscal engagement reduced reported revenue; the amount was already provided for as project expenses, so profitability was unaffected.
• Brand Activation segment swung sharply negative: The segment declined 21.6% QoQ because one customer's brand launch program went on hold due to FDA regulatory hurdles (deferring \$0.7–\$0.8 million in revenue by roughly three quarters) and another sizable project concluded.
• Brand Activation is inherently lumpier: Unlike enterprise-wide engagements, this is brand-by-brand work, so a single brand's FDA issue or engagement end creates visible variability; management says not to read too much into marginal client-count declines.
• Enterprise business provides the floor: At 86.6% of revenue, the enterprise commercial and medical side is non-discretionary; pharma companies' spending on sales and marketing, regulatory, and medical affairs stays in the same ballpark regardless of cycles.

Manish Gupta: "The reality is that our business is nondiscretionary. In fact, it's completely on the other side."

Tectonic: Moving Up the Value Chain

• The proposition: Tectonic blends technology and AI with people-led expertise to capture upstream commercial content creation work traditionally done by agencies-of-record or specialized healthcare agencies, accessing an estimated 5–15% of pharma marketing budgets.
• Early traction is real: The offering generated over \$1 million in revenue in its first quarter from two top-20 customers, with advanced-stage conversations underway with three more.
• Why it beats agencies: Agencies are purely people-led; Indegene layers generative AI on creative elements to make content more effective and execution more efficient, while global operations deliver cost benefits.
• Centralization unlocks AI: When clients work with 20 agencies, they cannot extract AI benefits; centralizing execution work enables AI, though agencies will still play a role in ideation and creative concepts.
• CultHealth integration proves the model: Acquired in 2022, CultHealth took 1.5–2 years to meld with Enterprise Commercial Solutions; clients now see clear consistency and cost benefits, validating the centralized-plus-technology thesis.

Manish Gupta: "This is Indegene's effort to move up the marketing value chain on commercial content creation side and capture more work upstream, which has traditionally been done by AORs or specialized health care agency, but this time, by use of our marketing and medical capabilities, global operations and technology, especially AI capabilities, we are making a decent impact in this area."

Demand Environment: Stabilizing After a Slow Period

• The post-COVID digestion is ending: After frantic activity through 2023, the industry consolidated and customers went slow; that is now easing and customers are coming back to the table, though decision-making is not yet fast.
• Existing relationships are the growth engine: Top 5 and top 20 customers are stable and growing; deals won in prior quarters are converting to revenue, and the engagement pipeline supports a comfortable growth outlook.
• C-level churn is localized, not systemic: C-level changes at clients affect only 1 or 2 accounts; one large customer that caused churn last year is now stabilizing, and the pipeline is growing even within that account.
• Patent cliff is an opportunity, not a threat: While the patent cliff exists, new launches are also slated to be high; Indegene has an omnichannel offering for mature brand categories and sees a very active pipeline for that work.
• Competitive moat is widening: Generic IT companies are not even in conversations; credible competition comes from CSOs, agencies, and contract research organizations, but Indegene differentiates by using digital AI instead of feet on the ground, with data on 0.2 crore physicians and algorithms for the shortest path to prescription.

Manish Gupta: "we don't like giving exact numbers and guidance, but we feel comfortable and good of where we are right now, right, in terms of our engagement pipeline."

Margins: Stable with a Growth-First Posture

• EBITDA margin held near 20%: Productivity initiatives including automation and Gen AI contributed to margin enhancement, offsetting wage bill hikes and annual rate resets on renewals every 3–5 years.
• PAT margin dipped on tax, not operations: A 30 bps sequential decline came from the effective tax rate rising to 23.5% from 21.2%; other income turned negative due to exchange loss on a weaker USD against the euro and INR.
• Wage hike impact lands next quarter: Salary increments took effect July 1, so the near-term margin impact will appear in Q2; management still expects to sustain around 20% EBITDA on a full-year basis.
• Growth trumps margin expansion: Incremental dollars will be reinvested into Tectonic, Gen AI, and organic capability expansion; these investments play into growth over a 3–5 year horizon, and medium-term margin expansion is a possibility, not a commitment.

Manish Gupta: "our priority is going to be growth rather than expansion of margins."

M&A: Sellers Are Finally Getting Realistic

• Valuation expectations are resetting: Companies held unrealistic value expectations driven by 2021–22 euphoria for a long period; deals did not happen, and management now clearly sees expectations coming down and becoming more realistic.
• Pipeline is healthy and dual-geography: The M&A pipeline spans both the U.S. and Europe, with discussions progressing to value zones Indegene is comfortable with; cash is not a deterrent.
• Acquisitions are capability-led, not geography-led: Management looks at targets from a capability perspective rather than for regional diversification, though the pipeline naturally includes both U.S. and European assets.
• Recent deals have been nonmaterial: MJL was described as a "really tiny thing" and a capability acquisition or acqui-hire; a large portion of historical growth has been organic, with inorganic acquisitions being nonmaterial.

Manish Gupta: "what we are seeing over here is interesting that companies for a very long period of time, well, had unrealistic expectations of value. They were still driven by the '21, '22 euphoria which had happened, right, in the private space. Deals haven't happened. And we clearly see that expectations coming down, right, and becoming more realistic."

AI & Strategic Initiatives: Building the Medium-Term Moat

• AI adoption is slow but structural: AI-based solutions are taking time to get adopted due to risk perception in pharma, but over the medium term, AI will play a very significant role in differentiating Indegene and enabling larger market share.
• Cortex is an enabler, not a standalone product: Management declined to give a measurable number for Cortex contribution, stating the priority is to transition offerings to be Gen AI enabled rather than track Cortex as a separate revenue line.
• Strategic sales reorganization completed: A remapping exercise of the sales function aims to drive higher effectiveness, traction, and efficiency; senior leaders are being added in consulting, data analytics, content, medical affairs, and regulatory affairs.
• FY26 initiatives are long-dated bets: Current investments may not have near-term impact but act as a better-off for medium- to long-term growth; the Indegene Digital Summit in Philadelphia on September 24 will showcase the CTO's presentation on Cortex and Gen AI direction.
• Headcount and revenue will decouple gradually: In the longer run, revenue growth and headcount growth will move in the same direction, but the pace of headcount addition need not match revenue growth as AI productivity scales.

Guidance & Commitments

Key Metrics